Clinical Trial Update: UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases [EARLY_Phase 1]

View source ↗

Summary

This entry describes an early-phase UCAR-T trial targeting CD19/BCMA for autoimmune hematologic diseases and notes that recruitment is ongoing. The study includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Evans Syndrome
• Immune Thrombocytopenia

Drugs mentioned

• UCAR-T

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura | EARLY_Phase 1 | Status: RECRUITING